No Data
Express News | Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics: Promising Growth With ICONIC Phase 3 Success and Strategic Partnerships
